文献速递慢性肾脏病

PCSK9与中度肾功能下降人群的心血管疾病

PCSK9 and Cardiovascular Disease in Individuals with Moderately Decreased Kidney Function.
PubMed 文献 · Clin J Am Soc Nephrol · 2022-04-06

在德国慢性肾脏病研究(GCKD)5138例白人参与者中,中位随访6.5年,PCSK9浓度与基线eGFR及白蛋白尿无关,但每升高100 ng/ml与现患心血管疾病风险升高及随访期主要不良心血管事件风险升高相关,且独立于传统危险因素(包括LDL胆固醇)。

要点

  • PCSK9浓度与基线eGFR和白蛋白尿均无关联。
  • 每100 ng/ml PCSK9升高,现患心血管疾病OR为1.22(95%CI 1.12–1.34;P<0.001)。
  • PCSK9第2–4四分位者主要不良心血管事件风险较第1四分位高32%–47%(P<0.05)。

核心结论

  • PCSK9与基线eGFR和白蛋白尿无关,但较高的PCSK9浓度与心血管疾病风险显著相关,且独立于包括LDL胆固醇水平在内的传统危险因素。

研究设计与样本

  • 德国慢性肾脏病研究(GCKD,DRKS 00003971)为队列研究,纳入5138例白人参与者,中位随访6.5年。
  • 入选标准为eGFR 30–60 ml/min per 1.73 m2,或eGFR>60 ml/min per 1.73 m2且伴明显蛋白尿(尿白蛋白-肌酐比值>300 mg/g或等效值)。

主要发现

  • 队列PCSK9浓度中位数为285 ng/ml(四分位距231–346 ng/ml)。
  • 每100 ng/ml PCSK9升高,现患心血管疾病(n=1284)的比值比为1.22倍(95%CI 1.12–1.34;P<0.001),该关联在非他汀使用者中强于他汀使用者(交互作用P=0.009)。
  • 随访期间474人发生主要不良心血管事件,PCSK9第2–4四分位者风险较第1四分位者高32%–47%(P<0.05)。
  • 亚组分析显示该关联仅限于基线时已有心血管疾病者(所有风险比>1.75;P=0.01)。
  • 将PCSK9加入扩展校正模型后,对现患心血管疾病(净重分类指数=0.27;95%CI 0.20–0.33)和随访期主要不良心血管事件(净重分类指数=0.10;95%CI 0.01–0.21)均有分类准确性的提升。

局限性

  • 原文在结论中称该关联在已有心血管疾病者中才成立,此为该研究的亚组分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of lipid homeostasis. Studies investigating the association between PCSK9 and cardiovascular disease in large cohorts of patients with CKD are limited. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The association of PCSK9 concentrations with prevalent and incident cardiovascular disease was investigated in 5138 White participants of the German Chronic Kidney Disease study with a median follow-up of 6.5 years. Inclusion criteria were eGFR of 30-60 or >60 ml/min per 1.73 m2 in the presence of overt proteinuria (urine albumin-creatinine ratio >300 mg/g or equivalent). Prevalent cardiovascular disease was defined as a history of nonfatal myocardial infarction, coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, carotid arteries interventions, and stroke. Incident major adverse cardiovascular disease events included death from cardiovascular causes, acute nonfatal myocardial infarction, and nonfatal stroke. RESULTS: Median PCSK9 concentration in the cohort was 285 ng/ml (interquartile range, 231-346 ng/ml). There was no association between PCSK9 concentrations and baseline eGFR and albuminuria. With each 100-ng/ml increment of PCSK9, the odds for prevalent cardiovascular disease (n=1284) were 1.22-fold (95% confidence interval, 1.12 to 1.34; P<0.001) higher in a model with extended adjustment for major confounders. This association was stronger in nonstatin than statin users (P value for interaction =0.009). During follow-up, 474 individuals experienced a major adverse cardiovascular disease event, and participants in PCSK9 quartiles 2-4 had a 32%-47% higher risk compared with those in quartile 1 (P<0.05). Subgroup analysis revealed that this association was restricted to those participants who already had cardiovascular disease at baseline (all hazard ratios >1.75; P=0.01). In addition, PCSK9 showed a valuable gain in classification accuracy for both prevalent cardiovascular disease (net reclassification index =0.27; 95% confidence interval, 0.20 to 0.33) and incident major adverse cardiovascular disease events during follow-up (net reclassification index =0.10; 95% confidence interval, 0.01 to 0.21) when added to an extended adjustment model. CONCLUSIONS: Our findings reveal no relation of PCSK9 with baseline eGFR and albuminuria but a significant association between higher PCSK9 concentrations and risk of cardiovascular disease independent of traditional risk factors, including LDL cholesterol levels.Clinical Trial registry name and registration number: German Chronic Kidney Disease Study (GCKD), DRKS 00003971.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Kheirkhah A, Lamina C, Kollerits B, et al. PCSK9 and Cardiovascular Disease in Individuals with Moderately Decreased Kidney Function. Clin J Am Soc Nephrol. 2022. PMID: 35387881. doi:10.2215/CJN.01230122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。